Coated Pills Or Tablets Patents (Class 424/474)
  • Patent number: 10231971
    Abstract: The present invention relates to a composition for preventing or treating dry eye syndrome or eye diseases caused by dry dyes, containing imatinib as an active ingredient and, more specifically, to an eye bath lotion for preventing or treating dry eye syndrome or eye diseases associated with dry eye syndrome, containing imatinib an active ingredient. Imatinib of the present invention effectively protects the corneal epithelia and inhibits the degeneration thereof, thereby being usable for a use of alleviating or treating dry eye syndrome or eye diseases associated with dry eye syndrome.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: March 19, 2019
    Assignee: AVIXGEN INC.
    Inventor: Mi Jeong Kim
  • Patent number: 10196360
    Abstract: Provided are crystal forms I, II, and III of bedaquiline fumarate, and preparation methods thereof. The crystal forms have high purity, excellent physicochemical properties, and good stability. The preparation methods can effectively improve the quality of products, and are applicable to preparation and mass production of medicines.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: February 5, 2019
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Jinyi Xu, Liang Zhang, Xiangyang Zhang, Xinzeng Wang, Jian Chai, Hongying Luo, Zhiqing Yang
  • Patent number: 10172958
    Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 8, 2019
    Assignee: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 10086087
    Abstract: A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: October 2, 2018
    Assignee: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 10039712
    Abstract: The present invention is drawn to a pharmaceutical composition comprising racecadotril, at least one surfactant and a lipid. The pharmaceutical composition is useful in treating diarrhea.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: August 7, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Der-Yang Lee
  • Patent number: 9974804
    Abstract: A strontium-based composition for controlling progression of osteoarthritis, osteoporosis, and tooth decay is presented. The composition may include a blend of ingredients including: at least 500 mg of strontium carbonate; citric acid; ascorbic acid; malic acid; folic acid; vitamin d3; magnesium citrate; natural sweetener; and flavoring. The all-natural strontium-based blend of ingredients is simply delivered to the oral cavity where an “in-vivo” chemical reaction takes place resulting in direct tooth and dentin exposure to facilitate direct dental anti-caries and anti-sensitivity strontium benefits. The blend of ingredients is then swallowed to establish intestinal transit and absorption to obtain the targeted benefits of systemic absorption to bone and joint areas.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 22, 2018
    Inventor: David Lloyd Smith
  • Patent number: 9969701
    Abstract: Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 15, 2018
    Assignees: Crystal Pharmatech Co., Ltd., Suzhou Pengxu Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Peng Wang, Pixu Li
  • Patent number: 9931358
    Abstract: The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: April 3, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Joseph Tyler, John S. Petersen
  • Patent number: 9913903
    Abstract: Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: March 13, 2018
    Assignee: Grifols Worldwide Operations Limited
    Inventors: Thomas Barnett, David A. Ross
  • Patent number: 9850252
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-?-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: December 26, 2017
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Bindu Bera, Jaroslaw Kanski, Andrea Martin
  • Patent number: 9839619
    Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 12, 2017
    Assignee: NEOS THERAPEUTICS, LP
    Inventors: Mark Tengler, Russell McMahen
  • Patent number: 9801819
    Abstract: A lipid composition comprising racecadotril, at least one surfactant and a lipid.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: October 31, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Der-Yang Lee
  • Patent number: 9675703
    Abstract: A particulate, pH-independent, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: June 13, 2017
    Assignee: TRIS PHARMA, INC
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 9675704
    Abstract: A particulate, pH-independent, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: June 13, 2017
    Assignee: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 9636300
    Abstract: A composition comprising racecadotril, at least one surfactant and a lipid.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Der-Yang Lee
  • Patent number: 9566299
    Abstract: The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) and less than of about 10% of plasticizing agent in coating. The invention also includes process of preparing such composition.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: February 14, 2017
    Assignee: WOCKHARDT LIMITED
    Inventors: Girish Kumar Jain, Venkataramana Naidu, Abdul Rehman Khan, Amar Agarwal, Srikanth Pattipati
  • Patent number: 9561204
    Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: February 7, 2017
    Assignee: ALPEX PHARMA S.A
    Inventors: Federico Stroppolo, Gabriele Granata, Shahbaz S. Ardalan
  • Patent number: 9549941
    Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: January 24, 2017
    Assignee: Gilead Pharmasset LLC
    Inventors: Darryl G. Cleary, Charles J. Reynolds, Miriam Michelle Berrey, Robert G. Hindes, William T. Symonds, Adrian S. Ray, Hongmei Mo, Christy M. Hebner, Reza Oliyai, Vahid Zia, Dimitrios Stefanidis, Rowchanak Pakdaman, Melissa Jean Casteel
  • Patent number: 9511039
    Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: December 6, 2016
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, Jerry Schneider
  • Patent number: 9511038
    Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: December 6, 2016
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, Jerry Schneider
  • Patent number: 9511019
    Abstract: A stable and/or synergistic pharmaceutical composition including: a) predinisolone metasulfobenzoate (PMSB) or its acceptable salts, preferably prednisolone metasulfobenzoate sodium and b) 5-ASA, derivatives or pharmaceutically acceptable salts thereof, which is suitable for rectal administration.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: December 6, 2016
    Assignees: NORDIC PHARMA, DISPHAR INTERNATIONAL BV
    Inventors: Hans Schram, Michael Ikechukwu Ugwoke, Laura Buttafoco
  • Patent number: 9439866
    Abstract: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: September 13, 2016
    Assignee: Angelini Pharma, Inc.
    Inventors: Sonia Gervais, Damon Smith, Miloud Rahmouni, Pauline Contamin, Rachid Ouzerourou, My Linh Ma, Angela Ferrada, Fouzia Soulhi
  • Patent number: 9415362
    Abstract: The invention concerns a process for the production of a tableting excipient with the following process steps: At least two of the following components are made available: A filler/binding agent; A lubricant; A flow regulating agent; A disintegrant; The available components are mixed together.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: August 16, 2016
    Assignee: J. Rittenmaier & Sohne GmbH & Co. KG
    Inventors: Edmont Stoyanov, Reinhard Vollmer, Tobias Götz
  • Patent number: 9320716
    Abstract: The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: April 26, 2016
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 9296686
    Abstract: The present invention relates to the preparation of (R)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: March 29, 2016
    Assignee: ARDEA BIOSCIENCES, INC.
    Inventors: Andreas Maderna, Jean Michel Vernier
  • Patent number: 9272051
    Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: March 1, 2016
    Assignees: California Institute of Technology, The Regents of the University of California, The United States Government Represented by the Department of Veterans Affairs
    Inventors: William A. Goddard, III, Mark Menna, Stephen Pandol, Ravinder Abrol
  • Patent number: 9248148
    Abstract: There is provided a composition or kit of parts comprising: one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract: and an iron hydroxypyrone, for increasing the level of iron in a patient's bloodstream and/or treating and/or preventing anaemia such as iron deficiency anaemia. A composition comprising iron hydroxypyrone is also provided for administration to a subject: having or at risk of having achlorhydria; wherein the gastric pH of the subject is equal to or greater than about 4; or wherein the subject has an inflammatory disease of the gastrointestinal tract.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: February 2, 2016
    Assignee: Iron Therapeutics Holdings AG
    Inventor: Michael Arthur Stockham
  • Patent number: 9198866
    Abstract: Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: December 1, 2015
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sreenivas S. Bhat, Xiaozhong Liang, Anthony Tutino, Anthony Joseph Frank
  • Patent number: 9192581
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: November 24, 2015
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 9089496
    Abstract: Pharmaceutical compositions of methylphenidate complexed with ion-exchange resin particles to form drug-resin particles are provided. The compositions have a first plurality of drug-resin particles that are uncoated and a second plurality of drug-resin particles that are coated with a delayed release coating.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: July 28, 2015
    Assignee: NEOS THERAPEUTICS, LP
    Inventors: Mark Tengler, Russell McMahen
  • Patent number: 9072680
    Abstract: Pharmaceutical compositions of methylphenidate complexed with ion-exchange resin particles to form drug-resin particles are provided. The compositions have a first plurality of drug-resin particles that are uncoated and a second plurality of drug-resin particles that are coated with a delayed release coating. Preferably, the second plurality of drug-resin particles are coated with a triggered-release coating triggered by a pH change and a diffusion barrier coating.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 7, 2015
    Assignee: NEOS THERAPEUTICS, LLP
    Inventors: Mark Tengler, Russell McMahen
  • Publication number: 20150147393
    Abstract: The present invention concerns palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing said oral veterinary compositions.
    Type: Application
    Filed: June 1, 2013
    Publication date: May 28, 2015
    Applicant: Ceva Sante Animale
    Inventors: Laurence Peyrot, Florence Guimberteau
  • Publication number: 20150147394
    Abstract: The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation, have superior content uniformity; and a preparation method thereof.
    Type: Application
    Filed: April 30, 2013
    Publication date: May 28, 2015
    Inventors: Je Hak Kim, Kyung Wan Nam, Seo Hun Park, Ju Won Kim, Sang Yeop Kim
  • Patent number: 9040085
    Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: May 26, 2015
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
  • Publication number: 20150132381
    Abstract: The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.
    Type: Application
    Filed: October 8, 2014
    Publication date: May 14, 2015
    Applicant: SALIX PHARMACEUTICALS, LTD
    Inventors: William Forbes, Enoch Bortey, Lorin K. Johnson
  • Publication number: 20150132378
    Abstract: The present invention relates to a multilayered coated tablet comprising at least three layers, i.e., first, second and third layer wherein the first and third layers contain at least one active pharmaceutical ingredient and the second layer is either a placebo or an immediate-release drug layer. Further, the tablet has a delayed-release coating, wherein the coating may contain one or more pore-forming agents and/or orifices on one or both sides. Furthermore, it may contain an immediate-release layer of the drug over the delayed-release coating layer. The present invention further relates to processes for preparing such a multilayered coated tablet.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 14, 2015
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Murali Krishna Bhavarisetti, Kumaravel Vivek, Sreekanth Narravula, Romi Barat Singh
  • Patent number: 9029355
    Abstract: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 12, 2015
    Assignee: Marinus Pharmaceuticals
    Inventors: Kenneth Shaw, Mingbao Zhang
  • Publication number: 20150125526
    Abstract: The present disclosure is directed to methods for treating inherited or acquired mitochondrial disease using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Patrice Rioux, Todd C. Zankel
  • Publication number: 20150125527
    Abstract: The present invention relates to solid orally administrable pharmaceutical administration forms comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (rivaroxaban, active compound (I)), characterized in that a partial amount of the active compound (I) is released rapidly and a partial amount is released in a controlled manner (modified, retarded, delayed), and to processes for their preparation, their use as medicaments and their use for the prophylaxis, secondary prophylaxis or treatment of disorders.
    Type: Application
    Filed: June 28, 2013
    Publication date: May 7, 2015
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Klaus Benke, Heike Neumann, Wolfgang Mück
  • Patent number: 9023391
    Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: May 5, 2015
    Assignee: Dexcel Ltd.
    Inventors: Valerie Azoulay, Erica Lahav
  • Publication number: 20150118307
    Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: May 27, 2014
    Publication date: April 30, 2015
    Applicant: SALIX PHARMACEUTICALS, LTD
    Inventors: Stephan D. Parent, Lisa Lynn McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared Peters Smit
  • Publication number: 20150118304
    Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a salt or complex thereof. The invention also relates to the combination of a broccoli extract or powder and magnesium or a salt or complex thereof. The invention provides compositions and methods relating to these combinations.
    Type: Application
    Filed: December 30, 2014
    Publication date: April 30, 2015
    Inventors: Brian CORNBLATT, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson, Ronald Kettenacker
  • Patent number: 9017722
    Abstract: A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 28, 2015
    Assignee: Intermune, Inc.
    Inventors: Gakuji Kiyonaka, Yoshihiro Furuya, Yusuke Suzuki
  • Publication number: 20150110872
    Abstract: The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The invention also relates to the combination of sulforaphane or a derivative thereof and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present invention also relates to the combination of a broccoli extract or powder and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present provides compositions and methods relating to these combinations.
    Type: Application
    Filed: December 30, 2014
    Publication date: April 23, 2015
    Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Patent number: 9011911
    Abstract: The present invention pertains to a high drug load tablet comprising an active ingredient Compound I of formula or a pharmaceutically acceptable salt thereof in an amount from about 30% to 80% in weight of the active moiety based on the total weight of the tablet.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: April 21, 2015
    Assignee: Novartis AG
    Inventors: Christian-Peter Luftensteiner, Jean-Claude Bianchi, Joerg Ogorka, Oskar Kalb
  • Publication number: 20150104507
    Abstract: A modified release formulation of lacosamide.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Inventors: Willi CAWELLO, Martin Alexander SCHUBERT
  • Publication number: 20150098996
    Abstract: A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke
  • Publication number: 20150098995
    Abstract: A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Particular anti-static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.
    Type: Application
    Filed: May 5, 2014
    Publication date: April 9, 2015
    Inventor: Stefan Lukas
  • Publication number: 20150093438
    Abstract: There is described a sub-analgesic amount of tramadol, or a salt thereof, in the treatment, alleviation or prevention of depression in a patient wherein the sub-analgesic amount is from about 60 to 80 mg, of tramadol or a salt thereof.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 2, 2015
    Inventors: Malcolm Philip Young, Philip McKeown
  • Patent number: 8992976
    Abstract: A pharmaceutical composition is provided according to the invention which is suited for the production of tablets by direct compression and which contains donepezil hydrochloride of polymorphic form I. The polymorphic form I of donepezil hydrochloride in the directly compressed tablet is also stable during long storage.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: March 31, 2015
    Assignee: ratiopharm, GmbH
    Inventors: Julia Schulze Nahrup, Frank Muskulus, Peter Kraass